Table 1 Clinical findings of DEB-TACE group and cTACE group
Variables | DEB-TACE (n = 56) | cTACE (n = 33) | P value |
|---|---|---|---|
Age (years) | 55.3 ± 11.6 | 56.1 ± 12.6 | 0.934 |
Gender (male/female) | 45/11 | 28/5 | 0.594 |
Tumor size (cm) | 11.2 ± 6.6 | 10.7 ± 5.8 | 0.588 |
Cirrhotic etiology (HBV/HCV/alcohol/PBC) | 49/5/2/0 | 27/3/2/1 | 0.624 |
ECOG ps (0/1 + 2) | 18/38 | 11/22 | 0.908 |
Total bilirubin (umol/L) | 24.5 ± 25.3 | 17.2 ± 9.0 | 0.055 |
Albumin (g/L) | 35.5 ± 5.0 | 35.7 ± 3.9 | 0.206 |
Creatinine (umol/L) | 70.8 ± 23.9 | 74.3 ± 20.9 | 0.403 |
Bilobar lesions (yes/no) | 32/24 | 15/18 | 0.286 |
Ascites (yes/no) | 26/30 | 11/22 | 0.226 |
Tumor burden (<50%/50–70%) | 41/15 | 27/6 | 0.356 |
Child-Pugh class (A/B) | 36/20 | 23/10 | 0.602 |
MELD score | 8.4 ± 1.7 | 8.8 ± 1.8 | 0.901 |
BCLC staging (B/C) | 8/48 | 5/28 | 1.000 |
PVTT (yes/no) | 47/9 | 27/6 | 0.797 |
Distant metastasis (yes/no) | 9/47 | 7/26 | 0.542 |
APS (yes/no) | 40/16 | 23/10 | 0.862 |
Received sorafenib (yes/no) | 3/53 | 2/31 | 1.000 |